To identify factors that impact on the timeliness and adequacy of haematuria evaluation.
Introduction
Bladder cancer is the eighth most common cancer in Australia, with an estimated 2880 new diagnoses and 1165 deaths from the disease in 2016 [1] . Patients with bladder cancer typically present with haematuria [2] , with visible haematuria occurring in 80% of cases [3] . There is a paucity of reputable local Australian guidelines for haematuria; however, recommendations worldwide generally suggest investigation with urine microscopy, culture and sensitivities (MCS), urine cytology, and renal tract imaging, followed by expedient urological referral with a view to cystoscopy [4] [5] [6] [7] . Patients deemed suitable for surgical management usually undergo transurethral resection of bladder tumour, with a recent Australian series showing that most patients have low-grade disease [8] .
Underlying bladder cancer is found in 4.0-4.8% and 15.0-19.3% of invisible and visible haematuria cases, respectively, with most due to benign or unknown causes [3, 9] . This reflects the non-specificity of haematuria as a clinical finding and highlights the uncertainty that many primary care physicians, such as GPs, may experience when deciding how thoroughly to investigate their patients and whether to refer to urology. This may explain why many patients with haematuria experience delays between their initial GP consultation and subsequent urology referral [10] .
Many studies have reported sub-optimal evaluation of patients with haematuria. Female gender has been associated with delayed referral to urology [10, 11] , decreased likelihood of undergoing imaging and cystoscopy [11] [12] [13] , and delayed bladder cancer diagnosis [12] . The importance of this is underscored by a greater proportion of women being diagnosed with more advanced-stage bladder cancer than men [14] , with overall poorer prognosis, even after controlling for disease stage [15] . Smokers, who are at an increased risk of bladder cancer [16] , are also less likely to be investigated thoroughly [17] . Given that both imaging and cystoscopic evaluation are integral to bladder cancer diagnosis, these findings are concerning for some patients. In consideration of this, our aim in the present study was to quantify the degree to which these factors influence delay to cystoscopy and receipt of recent investigations, and to identify other factors that may influence the haematuria evaluation, including age, socioeconomic status, anticoagulation status, and type of haematuria.
Patients and Methods
Our study was approved by Austin Health's Human Research Ethics Committee, in accordance with the National Health and Medical Research Council's National Statement on Ethical Conduct in Research Involving Humans [18] .
Using electronic medical records, we undertook a retrospective cohort study at Austin Health, a tertiary centre in metropolitan Melbourne, Australia. Patients aged ≥18 years who underwent cystoscopy primarily for investigation of haematuria between 1 January 2015 and 31 December 2015 were included. Exclusion criteria included patient age <18 years; known history of bladder, urinary tract or renal cancer; cystoscopy for indications other than haematuria and unknown date of urology consultation. Type of haematuria was sub-categorised into visible or invisible. Visible haematuria was defined as observable blood in the urine, as reported in medical notes and correspondences. Invisible haematuria was defined as 'no observable blood in urine' in notes or no definitive evidence of haematuria.
Patient level data were collected including date of birth, gender, socioeconomic status (SES), smoking status (ever vs never), anticoagulation status (aspirin or other including warfarin and clopidogrel), and type of haematuria. The location of initial presentation was recorded (e.g. GP, Emergency etc.). SES level was assigned by mapping the patient's residential postcode to an Australian Bureau of Statistics metric, the Index of Relative Socio-economic Advantage and Disadvantage (IRSAD) [19] . Dates of urology referral, urology consultation and cystoscopy were collected. Dates and results of investigations (imaging studies, urine MCS and urine cytology) conducted before cystoscopies were collected, if undertaken. Included imaging comprised CT of the abdomen and pelvis, kidney/ureters/bladder or IVU, as well as ultrasonography (US) of the abdomen, pelvis or renal tract. 'Suspicious findings on imaging' was defined as possible or likely underlying urological malignancy as given by radiology reports, medical notes or other correspondences.
The primary outcomes for of our study were: (i) time from GP referral to urology consultation, (ii) time from urology consultation to cystoscopy, and (iii) receipt of investigations 180 days prior to cystoscopy.
Data analysis
Baseline characteristics of the study population were summarised using standard descriptive statistics, including medians and interquartile ranges (IQRs) for continuous variables and percentages for categorical variables. Evaluation of the time interval outcomes was performed using negative binomial regressions with robust standard errors due to expected over dispersion. For time from GP referral to urology consultation analysis, the exposures selected were age at referral, gender, smoking status, SES, anticoagulation status, visible vs invisible haematuria, and if suspicious imaging findings were present 90 days before referral or in the interval between referral and urology consultation. This time frame was chosen to allow for any GP-ordered imaging done after the referral was made. For time from urology consultation to cystoscopy, the above exposures were again used but with the imaging time-frame 180 days before cystoscopy, accounting for any new urologist-initiated imaging. For both analyses, each exposure was assessed univariably and then all variables were entered simultaneously into a multivariable model. To evaluate receipt of recent investigations, we recorded whether or not CT, US, urine MCS and urine cytology were performed in the 180 days before cystoscopy. Differences between the exposures were examined with the chi-square test. Age and SES were entered as continuous variables in the multivariable model and as dichotomous variables in the univariable models and receipt of investigations analysis. Patients were split at 65 years for age and at the 50th percentile for SES. Analyses were performed using Stata v13.0SE (College Station, TX, USA). All tests were two-sided, with significance set at P < 0.05.
Results
We identified 1680 cystoscopy cases, of which 305 (18%) met the study criteria. Of the 1375 excluded cases, 793 had known history of bladder or urinary tract cancer, eight had known history of renal cancer, 571 had cystoscopy for indications other than haematuria and three had no recorded date of urology consultation. The study cohort included 225 men (74%) and 80 women (26%). Of these, 229 (75%) were 20 © 2017 The Authors BJU International © 2017 BJU International investigated for visible haematuria and 76 (25%) for invisible haematuria. The median (IQR) age of patients at the time of cystoscopy was 69.0 (55.6-78.2) years. Most patients were referred to urology from the general practice setting (64%); however, data were incomplete for 53 of these patients (27%) and were not part of the interval between referral and consultation analysis. Patient characteristics of the entire cohort and for the GP referrals with complete information are summarised in Table 1 .
Interval between GP referral and urology consultation
The median (IQR) interval between GP referral and urology consultation was 38 (19-87) days, with 35 (24%) patients having a lag time of >90 days. Women had a longer median interval (65 vs 33.5 days), as did patients with invisible vs visible haematuria (53 vs 33 days) ( Table 2) . Patients with a positive smoking history and those on anticoagulation had a significantly shorter time interval in univariable analysis. Patients with imaging suspicious for malignancy had a short median interval of 13 days. In the multivariable model, only type of haematuria and suspicious imaging retained significance (Table 3) . Gender and smoking status were no longer significant, due in considerable part to the differing proportions of invisible haematuria between women and men (63% vs 23%) and between never smokers and past or current smokers (38% vs 28%). Hence, we observed type of haematuria to be a stronger predictor.
Interval between urology consultation and cystoscopy
The median (IQR) interval between urology consultation and cystoscopy was 28 (21-54) days, with 52 (17%) patients having a delay of >90 days. The median interval difference was less than 9 days in all exposure subgroup comparisons ( Table 2) . Patients with visible haematuria and suspicious imaging were more likely to have their cystoscopy procedure quicker, but only the imaging variable was independently predictive (Table 3) .
Receipt of recent investigations
In the 180 days prior to cystoscopy, 58% of patients received CT or US, 59% recorded a urine MCS and 24% urine cytology (Table 4) . Patients on anticoagulation were significantly more likely to have imaging performed, although this was driven only by differences in US not CT. They were also more likely to have urine cytology. Older patients (aged >65 years) received proportionally more US and urine MCS investigations. There were no significant differences in any investigations between genders, ever or never smokers, or high and low SES patients.
Discussion
Haematuria is the strongest predictor of bladder cancer [3, 9] , with up to 22.1% of males and 8.3% of females with visible haematuria, and 4.8% of patients with invisible haematuria having underlying disease [3, 20] . This highlights the importance of an appropriate haematuria evaluation of which our present study provides an Australian perspective on both its timeliness and thoroughness. We identified that female gender was not associated with sub-optimal haematuria assessment, while those on anticoagulation had a more thorough evaluation. Further, patients with visible haematuria appeared to be inadequately investigated. Our present findings indicate that female gender is not a significant independent predictor of delayed or inadequate haematuria assessment. Women experienced greater time to urological review after GP referral. However, this was largely due to women being more likely to present with invisible haematuria and men with visible haematuria. Our present results are inconsistent with much of the current literature. Using Surveillance, Epidemiology and End Results (SEER) public cancer registry data linked with Medicare claims, Garg et al. [11] assessed 35 646 American patients aged ≥66 years who had a claim for haematuria within 1 year preceding bladder cancer diagnosis. They identified that women waited longer to see a urologist after their haematuria claim [adjusted hazard ratio (HR) 0.90, 95% CI 0.87-0.92, P < 0.001) and were more likely to experience delays in evaluation with cystoscopy, upper tract imaging and urine cytology [adjusted odds ratio (OR) 1.12, 95% CI 1.05-1.20, P < 0.001]. Although in our present model, we adjusted for the presence of imaging suspicious for cancer, a very strong predictor. Similar results have been reported in subsequent high-volume series [12, 21] . A further SEER-Medicare study identified that women waited 72.2 days (mean) between haematuria/UTI symptomatology and bladder cancer diagnosis, compared with 58.9 days for men [22] . A higher rate of UTI diagnosis and treatment in women [12, [22] [23] [24] is likely to contribute to their increased delays. However, in our present cohort we did not observe significant differences in UTI symptom prevalence (data not shown) or receipt of urine MCS *Imaging done 90 days prior to GP referral to urology consult for first analysis. Imaging done 180 days prior to cystoscopy for second analysis.
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© 2017 The Authors BJU International © 2017 BJU International investigation between genders. Moreover, a major limitation with the studies using the SEER database is their inability to consistently differentiate between visible and invisible haematuria. This is important, as clinical guidelines suggest a more thorough initial evaluation of visible haematuria [4] [5] [6] [7] . Therefore, our present study highlights the likely confounding effect of type of haematuria and gender disparities on the timeliness and adequacy of haematuria assessment.
Our present data also showed that patients on anticoagulation were more likely to receive imaging studies (in particular US) and cytology. Friedlander et al. [13] reported an association between anticoagulant use and receipt of imaging (OR 1.72, 95% CI 1.06-2.78), which was consistent with our present findings. For time to urological review after GP referral, we identified a trend for anticoagulated patients to be evaluated sooner than those without anticoagulation. Similar findings have been poorly reported in contemporary literature. It is not unreasonable for clinicians to attribute the cause of haematuria to anticoagulation therapy in patients on treatment. As such, these patients may be subject to greater assessment delays. However, anticoagulation within the therapeutic range has been shown not to predispose patients to haematuria [25] and the finding of haematuria in appropriately anticoagulated patients should not preclude standard assessment practices [26] . From our present results, we noted that patients on anticoagulation were evaluated more thoroughly and were not subject to delays in their haematuria evaluation. This may reflect clinicians adopting a more aggressive approach to anticoagulated patients, given their potential for bleeding complications.
Finally, given that visible haematuria warrants urinary tract imaging in all patients [4] [5] [6] [7] , we noted that only 61% of our visible haematuria patients had imaging conducted in the 6 months before cystoscopy. Our present result is lower than that reported by Shinagare et al. [27] , where 85% of patients with visible haematuria underwent imaging, although this was in a cohort where only 46% of the patients underwent cystoscopy. A survey of primary care physicians in the USA also revealed that only 38-41% of clinicians routinely ordered imaging studies for their patients with visible haematuria, while 20-25% routinely ordered imaging for those with invisible haematuria [28] . One possible explanation for these low rates of imaging could be that patients with recent and relevant imaging studies prior to their haematuria presentation did not require further repeat imaging. Moreover, some patients may have been unsuitable for certain types of imaging. Pregnant women, for example, have relative contraindication for studies involving ionising radiation, while claustrophobic patients may refuse CT due to enclosed spaces. It is important for future research to discern reasons for non-adherence to clinical guidelines.
To mitigate delays and inadequacies with haematuria assessment, dedicated haematuria clinics have been operating in the UK for many decades [29] , but are uncommon in Australia [30, 31] . Ooi et al. [30] introduced the first dedicated haematuria service in Western Australia in 2008 and showed that its 'one stop' haematuria clinic significantly reduced wait times for cystoscopy in a population where 10.2% of patients had underlying bladder cancer. Importantly, most patients (61.2%) were discharged after a single appointment. A prospective series in Victoria by Sapre et al. [31] corroborated similar findings, with 9.8% of patients found to have underlying bladder cancer and 42% discharged after a single point of contact. Both groups emphasise the Table 4 Receipt of investigations from 180 days prior to cystoscopy for the entire cohort.
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CT and/or US, n (%) (21) ability of dedicated haematuria clinics to efficiently streamline patient assessment and prioritise clinical urgency, enabling high-risk patients to be seen sooner. Given that patients referred more expediently for urological assessment have increased bladder cancer survival [32] , the widespread introduction of dedicated haematuria services in Australia may be worthwhile, albeit unlikely in the near future. Perhaps what needs to be addressed first is the lack of reputable local guidelines on haematuria. The USANZ is the peak urological body in Australia. Despite this, Gianduzzo et al. [33] identified that the general Australian public has limited understanding about the role of urologists and the USANZ in healthcare. It may be appropriate for an organisation like the USANZ to provide clinicians and the general population with educational resources to improve knowledge and public awareness about haematuria and bladder cancer.
Our present study has several limitations that should be acknowledged. Firstly, the study is confined to patients referred to a single public health service. Therefore, our findings may not be generalisable to the wider community, especially to patients seen privately or in rural settings. Despite this, we believe ours is the first report of an Australian cohort and is of value to Australian clinicians. Secondly, despite our best efforts at drawing upon all available sources of information, as a retrospective study using medical records, our study remains prone to errors of omission, coding errors, missing data and incorrect data. Finally, our data set did not include survival data and thus the oncological significance of our findings cannot be assessed in the present study.
Conclusion
Despite its decreasing incidence rate over the last few decades, bladder cancer still causes significant morbidity and mortality. Therefore, it is important that we remain vigilant in promptly managing the disease. In patients with haematuria, gender is not a significant independent predictor of sub-optimal evaluation, while those on anticoagulation therapy are evaluated more comprehensively. Of concern are patients with visible haematuria, who are inadequately imaged. A paucity of local haematuria guidelines may be a factor in its variable assessment. Therefore, improved education of both clinicians and the wider public is required to ensure that all patients with haematuria are evaluated appropriately.
